LAEKNA-B(02105): The first subject in the phase I multiple-dose extension study of LAE102 for the treatment of obesity has been dosed.

LAEKNA-B (02105) announced that the group has initiated the subject recruitment for the Phase I multiple-dose expansion study of LAE102 for the treatment of obesity in China, and the first subject has been dosed. This Phase I multiple-dose expansion study is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102 (subcutaneous injection) in 60 overweight/obese subjects. Subjects will be randomly assigned to either the LAE102 group or the placebo group and will receive treatment for 6 months. Based on the positive one-month treatment results observed in the previous MAD study, this pre-planned multiple-dose expansion study aims to further evaluate the efficacy and safety characteristics after longer-term continuous treatment. The group is dedicated to providing this precise treatment for obese or metabolic disease patients in need of new treatment options.